Examkin

Question

Difficulty: MediumHemodynamic and Coagulation Processes

A 29-year-old nulliparous woman is evaluated in the outpatient clinic for preconception counseling. Her medical history is significant for an unprovoked deep venous thrombosis in her right lower extremity three years ago, which was treated with a 6-month course of oral anticoagulation. She has no history of spontaneous bruising, epistaxis, or prolonged bleeding following minor injuries or dental procedures. Her physical examination is unremarkable. Laboratory studies obtained as part of her preconception workup reveal a normal prothrombin time (PT) and a platelet count of 210,000/mm³. However, her activated partial thromboplastin time (aPTT) is 58 seconds (normal: 25-40 seconds). An immediate 1:1 mixing study with normal pooled plasma fails to correct the aPTT into the normal reference range. Which of the following best describes the pathophysiologic mechanism responsible for this patient's abnormal coagulation assay?

  1. In vitro binding of immunoglobulins to phospholipid-protein complexesAnswer
  2. B
    Pathologic autoantibodies neutralizing the coagulant activity of factor VIII
  3. C
    Inherited qualitative defect or quantitative deficiency of von Willebrand factor
  4. D
    Systemic microvascular activation leading to consumption of procoagulant factors
  5. E
    Impaired hepatic gamma-carboxylation of glutamic acid residues on zymogens

Answer

The mechanism is the in vitro binding of immunoglobulins to phospholipid-protein complexes.
The correct answer accurately describes the mechanism of a lupus anticoagulant (LA) in antiphospholipid syndrome (APS). LAs are autoantibodies directed against phospholipid-binding proteins. In vitro, they bind to the phospholipids used in the aPTT assay, disrupting the assembly of the prothrombinase complex and thereby prolonging the clotting time. Because the etiology is a circulating antibody, adding normal plasma (mixing study) does not overcome the inhibition, and the aPTT remains prolonged. Paradoxically, in vivo, these antibodies activate endothelial cells, monocytes, and platelets, driving a hypercoagulable state characterized by recurrent venous or arterial thromboses (such as this patient's prior DVT) or adverse pregnancy outcomes.

Step-by-Step Solution

1
Analyze the patient's clinical history.
The patient has a history of an unprovoked deep venous thrombosis (prothrombotic state) with no history of bleeding diathesis.
Establishing the clinical phenotype helps rule out bleeding disorders and points toward hypercoagulable states.
2
Interpret the laboratory findings and the mixing study.
The patient has an isolated prolonged aPTT with a normal PT and normal platelets. The aPTT fails to correct on a 1:1 mixing study.
A failure to correct upon mixing with normal plasma indicates the presence of an inhibitor (such as an antibody) rather than a coagulation factor deficiency.
3
Correlate the clinical phenotype with the laboratory inhibitor profile.
The combination of an inhibitor (non-correcting aPTT) and a clinical history of thrombosis is highly specific for the presence of a lupus anticoagulant (antiphospholipid syndrome).
Factor inhibitors (like factor VIII antibodies) cause severe bleeding. Lupus anticoagulants cause an in vitro artifact (prolonged aPTT) but an in vivo prothrombotic tendency.

Key Concept

Patients with a lupus anticoagulant exhibit a paradoxical prolongation of the aPTT that fails to correct on a mixing study, despite having an in vivo hypercoagulable state that predisposes them to venous or arterial thrombosis.
Rate this question

Topics

Hemodynamic and Coagulation Processes

More questions from this topic